Skip to main content

Has gilteritinib been funded by Pharmac for the treatment of relapsed or refractory acute myeloid leukaemia in patients with an FLT3 (ITD or TKD) mutation; and if not, is it under consideration for funding?

Answered Question 18914 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Has gilteritinib been funded by Pharmac for the treatment of relapsed or refractory acute myeloid leukaemia in patients with an FLT3 (ITD or TKD) mutation; and if not, is it under consideration for funding?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

I am advised by Pharmac that it has not received an application for gilteritinib for this indication, and therefore it is not currently under consideration for funding.